Generic incretin medicines create a mass middle-income market
Non-originator incretin therapies become widely available and create a new obesity-treatment tier in middle-income countries.
Shared claim
Non-originator incretin therapies become widely available and create a new obesity-treatment tier in middle-income countries.
Timing assessment
Both agents place the transition in 2029.